KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Non-Current Debt (2016 - 2025)

Biolife Solutions (BLFS) has disclosed Non-Current Debt for 12 consecutive years, with $2.5 million as the latest value for Q1 2025.

  • Quarterly Non-Current Debt fell 84.06% to $2.5 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Mar 2025, down 84.06% year-over-year, with the annual reading at $5.0 million for FY2024, 71.54% down from the prior year.
  • Non-Current Debt for Q1 2025 was $2.5 million at Biolife Solutions, down from $5.0 million in the prior quarter.
  • The five-year high for Non-Current Debt was $24.2 million in Q3 2022, with the low at $916000.0 in Q1 2021.
  • Average Non-Current Debt over 5 years is $12.1 million, with a median of $7.8 million recorded in 2024.
  • The sharpest move saw Non-Current Debt skyrocketed 869.92% in 2021, then tumbled 84.06% in 2025.
  • Over 5 years, Non-Current Debt stood at $6.4 million in 2021, then surged by 274.52% to $23.8 million in 2022, then dropped by 26.19% to $17.6 million in 2023, then crashed by 71.54% to $5.0 million in 2024, then tumbled by 49.99% to $2.5 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $2.5 million, $5.0 million, and $7.8 million for Q1 2025, Q4 2024, and Q3 2024 respectively.